Business Context and Reporting Period
This Form 8-K is filed by Second Sight Medical Products, Inc. (not Vivani Medical, Inc.) on July 14, 2022. The report discloses a specific event regarding federal research funding rather than a standard quarterly or annual financial period.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed is:
- NIH Grant Funding: $1.1 million received for Year 4 of a five-year grant (Total planned: $6.4 million).
- Grant Purpose: Funding is primarily used to pay UCLA and Baylor College of Medicine for the Early Feasibility Clinical Trial of a Visual Cortical Prosthesis (Orion Study).
Material Changes
The material change reported is the receipt of notification from the National Institutes of Health (NIH) regarding the release of the fourth-year funding tranche for grant 5UH3NS103442. This represents a continuation of the planned five-year funding schedule.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) confirming the funding to support the Orion Study clinical trial.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard reliance on grant funding for clinical trial operations. The text does not provide forward-looking guidance on revenue or profitability.
Investor Verification Checklist
- Verify the total remaining balance of the $6.4 million NIH grant and the schedule for future disbursements.
- Confirm the current status and enrollment progress of the Orion Study Early Feasibility Clinical Trial.
- Review the Company's most recent 10-K or 10-Q filings for comprehensive liquidity, cash burn, and debt positions, as this 8-K does not contain them.
- Check for any conditions attached to the NIH funding that could impact future research milestones.